TY  - GEN
AU  - Florman,Sander
AU  - Vincenti,Flavio
AU  - Durrbach,Antoine
AU  - Abouljoud,Marwan
AU  - Bresnahan,Barbara
AU  - Garcia,Valter Duro
AU  - Mulloy,Laura
AU  - Rice,Kim
AU  - Rostaing,Lionel
AU  - Zayas,Carlos
AU  - Calderon,Kellie
AU  - Meier-Kriesche,Ulf
AU  - Polinsky,Martin
AU  - Yang,Lingfeng
AU  - Medina Pestana,Jose
AU  - Larsen,Christian P
TI  - Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT
SN  - 1399-0012
PY  - 2019///0812
KW  - Abatacept
KW  - administration & dosage
KW  - Black or African American
KW  - statistics & numerical data
KW  - Cyclosporine
KW  - Ethnicity
KW  - Female
KW  - Follow-Up Studies
KW  - Glomerular Filtration Rate
KW  - Graft Rejection
KW  - drug therapy
KW  - Graft Survival
KW  - drug effects
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Incidence
KW  - Kidney Failure, Chronic
KW  - surgery
KW  - Kidney Function Tests
KW  - Kidney Transplantation
KW  - methods
KW  - Male
KW  - Middle Aged
KW  - Postoperative Complications
KW  - Prognosis
KW  - Risk Factors
KW  - Survival Rate
KW  - Time Factors
KW  - Transplant Recipients
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/ctr.13225
ER  -